A meta-analysis by Pan et al. published in January 2017 [9] concluded that carriers of CYP2C19 LOF SNPs have a higher risk of stroke and vascular events than non-carriers among clopidogrel-treated patients with previous strokes or transient ischemic attacks. This evidence concerns the gene CYP2C19 and Stroke.